List of Tables
    Table 1. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Trends
    Table 3. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Drivers
    Table 4. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Challenges
    Table 5. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Restraints
    Table 6. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Targeted Drug EGFR RTK Inhibitors for NSCLC Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Player, 2017-2022
    Table 13. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Targeted Drug EGFR RTK Inhibitors for NSCLC by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC as of 2021)
    Table 15. Top Players of Targeted Drug EGFR RTK Inhibitors for NSCLC in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Targeted Drug EGFR RTK Inhibitors for NSCLC Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Targeted Drug EGFR RTK Inhibitors for NSCLC Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Targeted Drug EGFR RTK Inhibitors for NSCLC Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Beta Pharma Company Details
    Table 31. Beta Pharma Business Overview
    Table 32. Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 33. Beta Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 34. Beta Pharma Recent Development
    Table 35. AstraZeneca Company Details
    Table 36. AstraZeneca Business Overview
    Table 37. AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 38. AstraZeneca Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 39. AstraZeneca Recent Development
    Table 40. Natco Pharma Company Details
    Table 41. Natco Pharma Business Overview
    Table 42. Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 43. Natco Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 44. Natco Pharma Recent Development
    Table 45. Qilu Pharmaceutical Company Details
    Table 46. Qilu Pharmaceutical Business Overview
    Table 47. Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 48. Qilu Pharmaceutical Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 49. Qilu Pharmaceutical Recent Development
    Table 50. Genentech (Roche Group) Company Details
    Table 51. Genentech (Roche Group) Business Overview
    Table 52. Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 53. Genentech (Roche Group) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 54. Genentech (Roche Group) Recent Development
    Table 55. Mylan Company Details
    Table 56. Mylan Business Overview
    Table 57. Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 58. Mylan Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 59. Mylan Recent Development
    Table 60. Teva Company Details
    Table 61. Teva Business Overview
    Table 62. Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 63. Teva Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 64. Teva Recent Development
    Table 65. OSI Pharmaceuticals Company Details
    Table 66. OSI Pharmaceuticals Business Overview
    Table 67. OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 68. OSI Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 69. OSI Pharmaceuticals Recent Development
    Table 70. Glenmark Pharmaceuticals Company Details
    Table 71. Glenmark Pharmaceuticals Business Overview
    Table 72. Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 73. Glenmark Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 74. Glenmark Pharmaceuticals Recent Development
    Table 75. Beacon Pharmaceuticals Company Details
    Table 76. Beacon Pharmaceuticals Business Overview
    Table 77. Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 78. Beacon Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 79. Beacon Pharmaceuticals Recent Development
    Table 80. Boehringer Ingelheim Company Details
    Table 81. Boehringer Ingelheim Business Overview
    Table 82. Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 83. Boehringer Ingelheim Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 84. Boehringer Ingelheim Recent Development
    Table 85. Pfizer Company Details
    Table 86. Pfizer Business Overview
    Table 87. Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 88. Pfizer Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 89. Pfizer Recent Development
    Table 90. ARIAD Pharmaceuticals (Takeda) Company Details
    Table 91. ARIAD Pharmaceuticals (Takeda) Business Overview
    Table 92. ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 93. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 94. ARIAD Pharmaceuticals (Takeda) Recent Development
    Table 95. Genvio Pharma Limited Company Details
    Table 96. Genvio Pharma Limited Business Overview
    Table 97. Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 98. Genvio Pharma Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 99. Genvio Pharma Limited Recent Development
    Table 100. Drug International Limted Company Details
    Table 101. Drug International Limted Business Overview
    Table 102. Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 103. Drug International Limted Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 104. Drug International Limted Recent Development
    Table 105. Everest Pharmaceuticals Company Details
    Table 106. Everest Pharmaceuticals Business Overview
    Table 107. Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 108. Everest Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 109. Everest Pharmaceuticals Recent Development
    Table 110. Incepta Pharmaceuticals Limited Company Details
    Table 111. Incepta Pharmaceuticals Limited Business Overview
    Table 112. Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 113. Incepta Pharmaceuticals Limited Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 114. Incepta Pharmaceuticals Limited Recent Development
    Table 115. Cipla Pharma Company Details
    Table 116. Cipla Pharma Business Overview
    Table 117. Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 118. Cipla Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 119. Cipla Pharma Recent Development
    Table 120. Dr Reddy's Laboratories Company Details
    Table 121. Dr Reddy's Laboratories Business Overview
    Table 122. Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 123. Dr Reddy's Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 124. Dr Reddy's Laboratories Recent Development
    Table 125. Zydus Cadila Company Details
    Table 126. Zydus Cadila Business Overview
    Table 127. Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 128. Zydus Cadila Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 129. Zydus Cadila Recent Development
    Table 130. Hetero Drugs Company Details
    Table 131. Hetero Drugs Business Overview
    Table 132. Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 133. Hetero Drugs Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 134. Hetero Drugs Recent Development
    Table 135. Intas Pharmaceuticals Company Details
    Table 136. Intas Pharmaceuticals Business Overview
    Table 137. Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 138. Intas Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 139. Intas Pharmaceuticals Recent Development
    Table 140. Alkem Laboratories Company Details
    Table 141. Alkem Laboratories Business Overview
    Table 142. Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 143. Alkem Laboratories Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 144. Alkem Laboratories Recent Development
    Table 145. RPG Life Sciences Company Details
    Table 146. RPG Life Sciences Business Overview
    Table 147. RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 148. RPG Life Sciences Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 149. RPG Life Sciences Recent Development
    Table 150. Fresenius Kabi India Company Details
    Table 151. Fresenius Kabi India Business Overview
    Table 152. Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product
    Table 153. Fresenius Kabi India Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
    Table 154. Fresenius Kabi India Recent Development
    Table 155. Research Programs/Design for This Report
    Table 156. Key Data Information from Secondary Sources
    Table 157. Key Data Information from Primary Sources
List of Figures
    Figure 1. Targeted Drug EGFR RTK Inhibitors for NSCLC Product Picture
    Figure 2. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2017-2028 (US$ Million)
    Figure 4. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size 2017-2028 (US$ Million)
    Figure 6. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share in Global 2017-2028
    Figure 7. Targeted Drug EGFR RTK Inhibitors for NSCLC Report Years Considered
    Figure 8. Product Picture of Icotinib
    Figure 9. Product Picture of Gefitinib
    Figure 10. Product Picture of Erlotinib
    Figure 11. Product Picture of Afatinib
    Figure 12. Product Picture of Osimertinib
    Figure 13. Product Picture of Brigatinib
    Figure 14. Product Picture of Other
    Figure 15. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type in 2022 & 2028
    Figure 16. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2017-2028) & (US$ Million)
    Figure 17. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2017-2028)
    Figure 18. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type in 2022 & 2028
    Figure 19. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2017-2028) & (US$ Million)
    Figure 20. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Type (2017-2028)
    Figure 21. Product Picture of Squamous Cell Carcinoma of NSCLC
    Figure 22. Product Picture of Adenocarcinoma of NSCLC
    Figure 23. Product Picture of Large Cell Carcinoma of NSCLC
    Figure 24. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application in 2022 & 2028
    Figure 25. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2017-2028) & (US$ Million)
    Figure 26. Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2017-2028)
    Figure 27. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application in 2022 & 2028
    Figure 28. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2017-2028) & (US$ Million)
    Figure 29. United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2017-2028)
    Figure 30. North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 31. U.S. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 32. Canada Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 34. Germany Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. France Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. U.K. Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. Italy Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. Russia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. Asia-Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 40. China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. South Korea Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Australia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Taiwan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Indonesia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Thailand Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Malaysia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Philippines Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Latin America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 51. Mexico Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Brazil Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Argentina Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Middle East & Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 55. Turkey Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Saudi Arabia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 57. U.A.E Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 58. Beta Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 59. AstraZeneca Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 60. Natco Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 61. Qilu Pharmaceutical Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 62. Genentech (Roche Group) Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 63. Mylan Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 64. Teva Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 65. OSI Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 66. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 67. Beacon Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 68. Boehringer Ingelheim Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 69. Pfizer Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 70. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 71. Genvio Pharma Limited Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 72. Drug International Limted Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 73. Everest Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 74. Incepta Pharmaceuticals Limited Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 75. Cipla Pharma Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 76. Dr Reddy's Laboratories Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 77. Zydus Cadila Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 78. Hetero Drugs Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 79. Intas Pharmaceuticals Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 80. Alkem Laboratories Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 81. RPG Life Sciences Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 82. Fresenius Kabi India Revenue Growth Rate in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2017-2022)
    Figure 83. Bottom-up and Top-down Approaches for This Report
    Figure 84. Data Triangulation
    Figure 85. Key Executives Interviewed